AI Terminal
Marinomed Biotech AG
Share Issue/Capital Change • Sep 2, 2024
749_rns_2024-09-02_60a39a42-aa98-43c9-be97-eb67c897dae7.html
Share Issue/Capital Change
Open in ViewerOpens in native device viewer
News Details
Ad-hoc | 2 September 2024 17:46
Marinomed Biotech AG evaluates possible 10% capital increase with exclusion of statutory subscription rights
Marinomed Biotech AG / Key word(s): Corporate Action
Marinomed Biotech AG evaluates possible 10% capital increase with exclusion of statutory subscription rights
02-Sep-2024 / 17:46 CET/CEST
Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by EQS News – a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.
Korneuburg, Austria, 02. September 2024 – Marinomed Biotech AG (the “Company”) announces that the Management Board decided today to evaluate a capital increase of up to 154,053 new shares to be issued from the Authorized Capital 2024, subject to the direct exclusion of statutory subscription rights of existing shareholders, to finance the ongoing costs in the restructuring proceedings, to finance part of the restructuring plan proposal and for costs of continuing operations. This corresponds to up to 10% of the Company’s existing share capital.
For the purpose of the evaluation, the Management Board will enter into discussions with selected investors regarding the potential transaction and the transaction documentation. The actual implementation of the capital increase depends on the outcome of these discussions and is subject to further resolution by the Management Board and approval of the Supervisory Board. In addition, the restructuring proceedings require the approval of the restructuring administrator. These approvals have not yet been obtained.
If the capital increase is implemented, the Management Board is considering a possible second capital increase of 10% of the Company’s existing share capital, with exclusion of the statutory subscription rights of existing shareholders.
+++ End of ad-hoc announcement +++
End of Inside Information
02-Sep-2024 CET/CEST News transmitted by EQS Group AG. www.eqs.com
| Language: | English |
| Company: | Marinomed Biotech AG |
| Hovengasse 25 | |
| 2100 Korneuburg | |
| Austria | |
| Phone: | +43 2262 90300 |
| E-mail: | [email protected] |
| Internet: | www.marinomed.com |
| ISIN: | ATMARINOMED6 |
| WKN: | A2N9MM |
| Listed: | Regulated Unofficial Market in Berlin, Dusseldorf, Frankfurt, Munich, Stuttgart, Tradegate Exchange; Vienna Stock Exchange (Official Market) |
| EQS News ID: | 1979933 |
| End of Announcement | EQS News Service |